Amneal Pharmaceuticals Future Growth

Future criteria checks 1/6

Amneal Pharmaceuticals is forecast to grow earnings and revenue by 118.9% and 5.2% per annum respectively. EPS is expected to grow by 128% per annum. Return on equity is forecast to be 53.5% in 3 years.

Key information

118.9%

Earnings growth rate

128.0%

EPS growth rate

Pharmaceuticals earnings growth	27.6%
Revenue growth rate	5.2%
Future return on equity	53.5%
Analyst coverage	Low
Last updated	07 May 2024

Recent future growth updates

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Apr 16

Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management

Mar 30

Earnings and Revenue Growth Forecasts

NasdaqGS:AMRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,890	N/A	369	337	3
12/31/2025	2,790	23	304	332	4
12/31/2024	2,666	-84	264	186	4
3/31/2024	2,495	-169	124	201	N/A
12/31/2023	2,394	-84	276	346	N/A
9/30/2023	2,386	10	137	186	N/A
6/30/2023	2,312	-2	114	199	N/A
3/31/2023	2,272	-135	-5	84	N/A
12/31/2022	2,212	-130	-25	65	N/A
9/30/2022	2,139	-132	53	152	N/A
6/30/2022	2,122	-134	80	140	N/A
3/31/2022	2,098	2	161	214	N/A
12/31/2021	2,094	11	189	242	N/A
9/30/2021	2,067	14	219	285	N/A
6/30/2021	2,058	9	176	247	N/A
3/31/2021	1,987	-17	408	478	N/A
12/31/2020	1,993	91	313	379	N/A
9/30/2020	1,880	62	183	222	N/A
6/30/2020	1,739	-194	283	317	N/A
3/31/2020	1,679	-199	71	159	N/A
12/31/2019	1,626	-362	-96	2	N/A
9/30/2019	1,727	-339	200	312	N/A
6/30/2019	1,825	-67	97	234	N/A
3/31/2019	1,834	-69	19	115	N/A
12/31/2018	1,663	-21	153	250	N/A
9/30/2018	1,459	155	-46	56	N/A
6/30/2018	1,237	149	-32	67	N/A
3/31/2018	1,083	168	83	192	N/A
12/31/2017	1,034	168	N/A	234	N/A
9/30/2017	1,039	54	N/A	205	N/A
12/31/2016	1,018	207	N/A	115	N/A
12/31/2015	866	169	N/A	105	N/A
12/31/2014	786	177	N/A	112	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AMRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AMRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AMRX's revenue (5.2% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: AMRX's revenue (5.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (53.5%).

Amneal Pharmaceuticals Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 13% to US$8.25

Price target increased by 7.3% to US$7.31

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Price target increased by 50% to US$5.25

Recent updates

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$8.25

New major risk - Negative shareholders equity

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Price target decreased by 18% to US$4.20

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Amneal Pharmaceuticals: Risk Still Persists

Amneal Pharma reaffirms 2022 guidance

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Price target decreased to US$5.10

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment